Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CXCR4 | P61073 | 12/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9167025 | 0.91 | POLB (0.60) | POLBSMN1; SMN2CXCR4HRH3MEN1 | |
| SCHEMBL1393841 | 0.91 | — | — | |
| SCHEMBL9172023 | 0.91 | POLB (0.60) | POLBSMN1; SMN2CXCR4HRH3MEN1 | |
| Hydrochloric Acid SCHEMBL960566 | 0.89 | SMN1; SMN2 (0.58) | POLBSMN1; SMN2CXCR4HRH3MEN1 | |
| Hydrochloric Acid SCHEMBL2009370 | 0.89 | SMN1; SMN2 (0.58) | POLBSMN1; SMN2CXCR4HRH3MEN1 | |
| SCHEMBL9168067 | 0.89 | POLB (0.58) | POLBSMN1; SMN2CXCR4HRH3MEN1 | |
| SCHEMBL9172017 | 0.86 | POLB (0.56) | POLBSMN1; SMN2CXCR4HRH3MEN1 | |
| SCHEMBL18975385 | 0.79 | POLB (0.84) | POLBSMN1; SMN2CXCR4HRH3MEN1 | |
| SCHEMBL2000877 | 0.78 | CXCR4 (0.50) | POLBSMN1; SMN2CXCR4HRH3MEN1 | |
| SCHEMBL4205876 | 0.78 | CXCR4 (0.50) | POLBSMN1; SMN2CXCR4HRH3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820749-B2 | Centrally active and orally bioavailable uncharged bisoxime antidotes for organophosphate poisoning and methods for making and using them | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820749-B2 | Centrally active and orally bioavailable uncharged bisoxime antidotes for organophosphate poisoning and methods for making and using them | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820749-B2 | Centrally active and orally bioavailable uncharged bisoxime antidotes for organophosphate poisoning and methods for making and using them | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-11-21 | — | — | US | disclosed |
| US-20220227724-A1 | CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE UNCHARGED BISOXIME ANTIDOTES FOR ORGANOPHOSPHATE POISONING AND METHODS FOR MAKING AND USING THEM | OAK RIDGE NATIONAL LABORATORY | 2022-07-21 | — | — | US | disclosed |
| WO-2020237079-A1 | CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE UNCHARGED BISOXIME ANTIDOTES FOR ORGANOPHOSPHATE POISONING AND METHODS FOR MAKING AND USING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020237079-A1 | CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE UNCHARGED BISOXIME ANTIDOTES FOR ORGANOPHOSPHATE POISONING AND METHODS FOR MAKING AND USING THEM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-26 | — | — | WO | disclosed |
| EP-0595557-B1 | New substituted azetidinones as anti-inflammatory and antidegenerative agents | MERCK & CO INC (US) | 2004-06-30 | — | — | EP | disclosed |
| US-5747485-A | RESPIRATORY SYSTEM DISORDERS | MERCK & CO., INC. (US) | 1998-05-05 | — | — | US | disclosed |
| EP-0755262-A4 | COMPOSITION FOR THE TREATMENT OF LUNG DISEASE | MERCK & CO INC (US) | 1997-05-07 | — | — | EP | disclosed |
| EP-0755262-A1 | COMPOSITION FOR THE TREATMENT OF LUNG DISEASE | MERCK & CO. INC. (US) | 1997-01-29 | — | — | EP | disclosed |
| US-5591737-A | ELASTASE INHIBITORS | MERCK & CO., INC. (US) | 1997-01-07 | — | — | US | disclosed |
| WO-1995024207-A1 | COMPOSITION FOR THE TREATMENT OF LUNG DISEASE | MERCK & CO., INC. (US) | 1995-09-14 | — | — | WO | disclosed |
| WO-1994010142-A1 | NEW SUBSTITUTED AZETIDINONES AS ANTI-INFLAMMATORY AND ANTIDEGENERATIVE AGENTS | MERCK & CO., INC. (US) | 1994-05-11 | — | — | WO | disclosed |
| EP-0595557-A1 | New substituted azetidinones as anti-inflammatory and antidegenerative agents | MERCK & CO. INC. (US) | 1994-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227724-A1 | CENTRALLY ACTIVE AND ORALLY BIOAVAILABLE UNCHARGED BISOXIME ANTIDOTES FOR ORGANOPHOSPHATE POISONING AND METHODS FOR MAKING AND USING THEM | BCHE, ACHE, FHIT | POLB 1223/4885SMN1; SMN2 1520/4885CXCR4 3541/4885 |
| US-11820749-B2 | Centrally active and orally bioavailable uncharged bisoxime antidotes for organophosphate poisoning and methods for making and using them | BCHE, ACHE, FHIT | POLB 1223/4885SMN1; SMN2 1520/4885CXCR4 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.